Significantly reduce the level of STAT3 innovative protein degradation agent shows anti-cancer activity

Kymera Therapeutics today announced that the latest preclinical data shows that its STAT3-specific targeted degradation drugs have shown therapeutic potential in the treatment of abnormal STAT3-activated peripheral T-cell lymphoma (PTCL)

Kymera is developing selective STAT3 degradation drugs for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis

▲STAT3 has multiple roles in tumor survival and growth (picture source: reference [2])

The latest preclinical research results show:

Kymera has discovered a series of potent and selective STAT3 degradation agents, which are active against wild-type and clinically relevant mutant STAT3

STAT3 degrading agents can cause ALK-positive anaplastic large cell lymphoma (ALCL), NK/T-cell lymphomas carrying STAT3 mutants, and ALK-negative ALCL cell lines to arrest growth and increase cell death in vitro and in vivo

▲Stat3 degradant exhibited anti-cancer activity in mouse model (picture source: reference [2])

The signal pathway analysis of ALK-positive ALCL cells treated with STAT3 degradation agent showed that the cytokine response regulated by STAT3 decreased, the cell cycle characteristics continued to be down-regulated and the immune pathway was up-regulated

Kymera's main STAT3 degradation drug candidate KT-333 is currently in the preclinical development stage.

Note: The original text has been deleted

Reference materials:

[1] Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum.

[2] Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL.